Pi-Cardia

About

Funding history · 5 rounds · $37.0M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Pi-Cardia's core medical device technology?

Pi-Cardia develops a low-profile catheter for treating aortic stenosis. Its technology uses mechanical impact to fracture valve calcifications without damaging surrounding soft tissue, aiming to increase the valve's effective orifice area and eliminate the need for valve replacement.

When was Pi-Cardia founded and where is its headquarters located?

Pi-Cardia was founded in January 2009 and is headquartered in Rehovot, Israel.

What was the outcome of Pi-Cardia's first-in-human study with its Leaflex™ Catheter?

In May 2019, Pi-Cardia's first-in-human study demonstrated significant improvement in aortic valve function following treatment with its novel non-implant based Leaflex™ Catheter.

Which investors participated in Pi-Cardia's Series B funding round in September 2015?

Accelmed and Clal Biotechnology Industries (CBI) were investors in Pi-Cardia's Series B funding round in September 2015.

What was the value of Pi-Cardia's Series C financing round in April 2020 and who led it?

In April 2020, Pi-Cardia closed a $27 million Series C financing round, led by Sofinnova Partners.

What significant regulatory approval did Pi-Cardia receive in July 2022 for its ShortCut™ device?

In July 2022, Pi-Cardia received FDA IDE Approval for a pivotal study with its ShortCut™ device.

What partnership did Pi-Cardia form in July 2020 related to its heart valve technology?

In July 2020, Pi-Cardia partnered with China's Venus Medtech for its heart valve technology.

What product did Pi-Cardia successfully use for mitral valve splitting in August 2022?

In August 2022, Pi-Cardia successfully performed mitral valve splitting with its ShortCut™ device.

How many employees does Pi-Cardia currently have?

Pi-Cardia currently has 68 employees.

Sectors & technology

Highlights

Tags